Hsiaowei Deng
Overview
Explore the profile of Hsiaowei Deng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
528
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gibson C, Bahit M, Mehran R, Mehta S, Lamee R, Goto S, et al.
Am Heart J
. 2025 Feb;
285:21-28.
PMID: 39986336
Background: Despite current antiplatelet therapy, patients remain at risk of recurrent ischemic events after acute coronary syndromes (ACS), which may reflect persistently elevated thrombin generation. Factor XIa inhibition reduces thrombin...
2.
Yuan Z, Levitan B, Deng H, Szarek M, Bauersachs R, Berkowitz S, et al.
J Am Heart Assoc
. 2024 Apr;
13(8):e032782.
PMID: 38563380
Background: The VOYAGER PAD (Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of...
3.
Cunningham J, Ferreira J, Deng H, Anker S, Byra W, Cleland J, et al.
JACC Heart Fail
. 2020 Mar;
8(5):359-368.
PMID: 32171760
Objectives: This study investigated the effects of a mid-trial protocol amendment requiring elevated natriuretic peptides for inclusion in the COMMANDER-HF (A Study to Assess the Effectiveness and Safety of Rivaroxaban...
4.
Mehra M, Vaduganathan M, Fu M, Ferreira J, Anker S, Cleland J, et al.
Eur Heart J
. 2019 Aug;
40(44):3593-3602.
PMID: 31461239
Aims: Stroke is often a devastating event among patients with heart failure with reduced ejection (HFrEF). In COMMANDER HF, rivaroxaban 2.5 mg b.i.d. did not reduce the composite of first...
5.
Greenberg B, Neaton J, Anker S, Byra W, Cleland J, Deng H, et al.
JAMA Cardiol
. 2019 Apr;
4(6):515-523.
PMID: 31017637
Importance: Whether anticoagulation benefits patients with heart failure (HF) in sinus rhythm is uncertain. The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy...
6.
Neuen B, Ohkuma T, Neal B, Matthews D, de Zeeuw D, Mahaffey K, et al.
Circulation
. 2018 Jun;
138(15):1537-1550.
PMID: 29941478
Background: Canagliflozin is approved for glucose lowering in type 2 diabetes and confers cardiovascular and renal benefits. We sought to assess whether it had benefits in people with chronic kidney...
7.
Perkovic V, de Zeeuw D, Mahaffey K, Fulcher G, Erondu N, Shaw W, et al.
Lancet Diabetes Endocrinol
. 2018 Jun;
6(9):691-704.
PMID: 29937267
Background: In the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program, canagliflozin reduced the rates of major adverse cardiovascular events and the results suggested a renal benefit in patients with type 2...
8.
Neal B, Perkovic V, Matthews D, Mahaffey K, Fulcher G, Meininger G, et al.
Diabetes Obes Metab
. 2017 Jan;
19(3):387-393.
PMID: 28120497
Aims: The primary aim of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R) is to determine whether the favourable effects of inhibition of the sodium glucose co-transporter 2 (SGLT2) on blood glucose,...
9.
Jacobson A, Deng H, Lombard J, Lessig H, Black R
J Clin Endocrinol Metab
. 2010 Apr;
95(6):2596-606.
PMID: 20392867
Context: (123)I-mIBG scintigraphy has been in clinical use for more than 20 yr for diagnostic assessment of patients with neural crest and neuroendocrine tumors. Prospective validation of the performance characteristics...